Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of type II diabetes

US5700795A · kind A · utility

Assignees

• The General Hospital Corporation · US
• BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE · US

Inventors

• Anthony H. Cincotta · Baton Rouge, US
• Albert H. Meier · Baton Rouge, US
• John M. Wilson · Helotes, US

Key dates

• Filing date: Jun 1, 1995
• Grant date: Dec 23, 1997
• Expiry date: Jun 1, 2015

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N33/74
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are methods for improving various aberrant metabolic indices in mammals including humans by administration of muscarinic (particularly M1) receptor antagonists alone or in combination with prolactin inhibiting compounds. Preferably the administration takes place at a predetermined time (or, if a combination of muscarinic receptor antagonist and prolactin inhibitor is used, at different predetermined times) during a 24-hour period when the administration is effective (or its effect more pronounced). The invention has application in the treatment of lipid and glucose metabolism disorders.